Category Archives: Eczema

Findings from Facts and Factors reportAtopic Eczema Treatment Market By Type (Topical, Oral, and Injectable), By Application (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 2026states that the globalAtopic Eczema Treatment marketin 2019 was approximately USD 18,057.4 Million. The market is anticipated to grow at a CAGR of 10.36% and is anticipated to reach around USD 34,089.3 Million by 2026.

Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is more common in children and can become more serious as they get older. Atopic dermatitis is caused by a genetic mutation, environmental contamination, immune system dysfunction, and skin permeability issues. Dry skin, irritants, fatigue, allergies, infection, and heat/sweating are the primary causes of atopic dermatitis. Its important to remember that these just cause atopic dermatitis symptoms; they dont cause atopic dermatitis. Atopic dermatitis (AD) is a widespread chronic skin disorder that has been linked to other atopic diseases. Although there is growing evidence of a connection with non-atopic conditions, such as autoimmune disorders, data on many autoimmune diagnoses is restricted.

Dermatological disorders are exceedingly common in different forms all over the world. According to the World Health Organization, skin diseases affected over 900 million people in 2017. Atopic dermatitis is the most common of these diseases, affecting over 300 million people worldwide. Children make up about a quarter of the victims. The increased prevalence of this disease is projected to have a positive impact on the economy. In recent years, increased understanding of the diseases therapeutic options has aided the markets survival. Government initiatives to ensure quality and more affordable care, as well as the availability of favorable reimbursement plans, are expected to boost the sector. During the study era, developing country health growth and evolution would present new opportunities.

Request Download Link for PDF Sample Report With COVID-19 Impact Analysis Herehttps://www.fnfresearch.com/sample/atopic-eczema-treatment-market

The infected area produces white fluid, which necessitates treatment. Atopic dermis normally starts in childhood and gets worse as you get older. Atopic dermatitis is caused by a combination of genetics, environmental toxicity, immune system dysfunction, and skin permeability issues.

Based on type market is bifurcated into categories such as topical, oral, and injectable. A Topicalcategory is estimated to hold the largest market share of the atopic eczema treatment market. The cream-based solution for treatment is making the product easy for an application, which is expected to surge a market demand in forecast years. In addition to this, based on application, the market is bifurcated into categories such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Retail pharmacies are estimated to hold the largest market share of the atopic eczema market. However, online pharmacies are estimated to grow at a significant CAGR owing to the penetration of mobile phones and the emergence of numerous medicine delivery startups.

Because of new product releases, early treatment acceptance, and lifestyle improvements, North America was the largest market for the treatment of atopic dermatitis in 2019. North America emerged as the leading market for atopic dermatitis, owing to higher treatment knowledge among the target population, early acceptance of novel drugs, and better reimbursement policies, according to the regional study. Europe has the second-largest share of the market. The key driver of the demand in this area is large-scale R&D spending. The Asia-Pacific region is projected to rise the fastest between 2020 and 2026, owing to increasing demand. Due to increasing health expenditure and the availability of adequate care, the Asia-Pacific region is expected to rise the fastest between 2020 and 2026.

Inquire To Know Additional List of Market Players Included, Request Herehttps://www.fnfresearch.com/inquiry/atopic-eczema-treatment-market

Top Market Players

Some of the key players in the atopic eczema treatment market are Encore Dermatology Inc., AbbieVie Inc., LEO Pharma A/S, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline plc.,Sanofi S.A., Regeneron Pharmaceuticals Inc., LEO Pharma A/S, and Medimmune LLC. (AstraZeneca), among others. The aforementioned companies primary strategy for market growth is to invest in the research and production of new prescription products. Sanofi Genzyme, for example, makes the Biologics medication DUPIXNET , which treats skin lesions and relieves scratching.

According to the 2017 Global Burden of Disease research database, atopic eczema is the leading cause of skin-related impairment, affecting up to 24 percent of the global population, according to JAAD International. Up to 23% of nurses suffer from occupational dermatitis, with daily hand washing and the use of protective gloves being major risk factors. The COVID-19 pandemic has risen in cases of skin irritation and disease in health-care workers as a result of excessive use of personal protective equipment (PPE) and chronic stress, which exacerbates atopic eczema. Hand washing is a popular recommendation for preventing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is expected to affect more people than just health-care staff as dermatitis cases rise. As a result, the global COVID-19 pandemic is predicted to benefit the atopic eczema treatment industry.

This report segments the Atopic Eczema Treatment market as follows:

Global Atopic Eczema Treatment Market:By Type Based Segmentation Analysis:

Global Atopic Eczema Treatment Market: By Application Segmentation Analysis

Global Atopic Eczema Treatment Market: Regional Segmentation Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1 (347) 690-0211Email:sales@fnfresearch.comWeb:https://www.fnfresearch.com

Excerpt from:
Atopic Eczema Treatment Market projected to Reach USD 34089.3 Million by 2026 The Courier - The Courier

Accepting that having acne was my new normal, it opened up a portal in my life, says influencer Nazhaya Barce Barcelona. In the fall of her sophomore year of college, she returned to school with her face in an acne breakout that only worsened over time. I couldn't put my finger on the root of the issue for years," she recalls. "I blamed it on so many things: skin-care products, hair products, food, the water in my college town."

Unlike many of the other skin ailments featured in this piece, acne is something most people encounter (up to 85 percent of us, in fact). But, as Aguh explains, it can present differently on darker skin, and treatment may look different as well. While acne pimples look similar in all skin tones, Aguh explains, acne is more likely to leave behind spots of discoloration in more deeply pigmented skin tones, which feels like a problem caused by another problem. For this reason, when treating acne in brown skin, it is very important to use medications that will not only treat the active, inflamed acne pimples, but also are designed to treat the discoloration as well, says Diggs.

For Barcelona, a visit to the dermatologist meant she had medical intervention: "My first time going to the dermatologist, I was very excited to get a topical prescription that was medically engineered to clear my skin."

But a doctor's prescription can only do so much; treatment required work on her mental health too. Barcelona felt that acne had tainted her membership in the community of "beautiful people." With acne, Barcelona shares, "self-love and self-discovery presented itself to me in a way I would've never experienced if I had clear skin all my life." She explains, I had to navigate social interactions, romantic relationships, and self-reflection with a new face. Acne created a mental and spiritual wound that was very painful and uncomfortable to wear every day. It blinded me to who I really was.

Then, one day, Barcelona continues, "I decided to be brave. I was exhausted from trying to hide and feeling shame about how I looked. I told myself that I wasn't going to torture myself like this anymore. I wasn't sure if people really thought I looked as disgusting and scary as I thought I did, but I decided that day that even if they did, I didn't care anymore. I was beautiful before the acne, and I'll continue to be beautiful with it."

Read the original:
Black Women With Skin Conditions Share Their Paths to Diagnosis - Allure

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Four Indications in Clinical Development

JUPITER, FL / ACCESSWIRE / April 29, 2021 / Jupiter Wellness, Inc. (NASDAQ: JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced an update on its clinical pipeline of CBD-based therapeutic topical formulations including JW-100 for the treatment of eczema, JW-200 for skin cancer, JW-300 for burns, and JW-400 for herpes cold sores.

Commenced Patient Enrollment for Skin Cancer: Study Completion Expected Q4 2021

Jupiter's JW-200 is designed to provide action and relief in the treatment of Actinic Keratosis (AK), the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays. The objective of this double blinded, placebo-controlled study is to evaluate the efficacy of JW-200 in both the treatment and prevention of disease, with a primary efficacy endpoint of the percentage of patients with complete clearance of AK lesions. An estimated 120 adults diagnosed with AK will be recruited, with an expected study completion date of Q4 2021.

The Skin Cancer Foundation estimates 58 million Americans have one or more AK lesions which appear as raised, scaly discolored patches on sun-exposed skin. Left untreated, approximately 20% of AK lesions progress to squamous cell carcinoma. The skin cancer treatment market was $8.19 billion 2019 and is estimated to reach $14.55 billion by 2027.

Patient Recruitment Started for First Degree Burns: Topline Data Expected Q4 2021

JW-300 is being evaluated in a clinical study for the treatment of first-degree burns resulting from sun exposure. The double blinded, placebo-controlled trial is recruiting an estimated 44 patients who have first degree burns induced by UVB irradiation. The primary endpoint is the reduction in erythema within 24 hours of treatment. The trial is expected to be completed in Q3 2021, with topline data expected Q4 2021.

Preparing for Upcoming IND Meeting with U.S. FDA for Eczema Phase I/II Study

Jupiter is preparing for a meeting in Q3 2021 with the U.S. Food and Drug Administration (FDA) regarding the Company's Investigational New Drug (IND) application that it expects to file. The Company will propose its clinical protocol for a Phase I/II study based on the efficacy and safety shown in the recently completed exploratory study of JW-100 for the treatment of atopic dermatitis (eczema). The study showed that JW-100 cleared or reduced eczema following two weeks of use in more than half of the subjects, achieving ISGA clear or almost clear (1 or 2) with at least a 2-grade improvement from baseline after treatment, versus 20% and 15% in the CBD-only and placebo arms.

The global eczema market is valued at $10 billion and is expected to grow at a CAGR of 13% through 2025. Ten percent of the U.S. population, or 31.6 million people, have eczema, and according to NationalEczema.org, 86% of people are not satisfied with their current treatment.

JW-400 for Treatment of Herpes Cold Sores Expected to Commence Recruitment Q4 2021

The double blind, placebo controlled study is now preparing for recruitment of 40 patients with recurrent herpes labialis infection (HSV) who had their initial infection more than one year prior. The primary endpoint is the duration of the herpes labialis episode. The herpes simplex virus treatment market was $4.8 billion in 2017. Nearly half of Americans age14-29 have HSV-1, known as the cold sore virus.

"With multiple study completion and topline data milestones upcoming in 2021 and early 2022, we are very pleased with the pace and scope of our clinical programs which address substantial market opportunity and clinical needs for more effective therapies," stated Brian John, CEO of Jupiter Wellness.

About Jupiter Wellness

Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The Company's clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun" sunscreen and other wellness brands sold through its robust distribution platform.

For additional information, please visit http://www.jupiterwellnessinc.com. The Company's public filings can be found at http://www.Sec.gov.

Safe Harbor Statement

To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact InfoPhone: 561-244-7100Email: info@jupiterwellness.com

SOURCE: Jupiter Wellness, Inc.

View source version on accesswire.com: https://www.accesswire.com/643224/Jupiter-Wellness-Advances-Clinical-Pipeline-of-CBD-Based-Topical-Treatments

See the original post:
Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments - StreetInsider.com

The same ingredients in soap that break apart dirt and oils can also strip moisture and softness from your skin. To restore moisture, dairy ingredients like cows milk are sometimes added to the mix of your favorite bar soaps. Goats milk soap is simply a bar soap that has goats milk in the formula instead of cows milk.

Like other natural soaps, goats milk soap is made from lye thats mixed with fats and oils. In this case, the fats in the soap come at least in part from goats milk.

Since goats milk has a different molecular structure than cows milk, some people with a cows milk sensitivity prefer it. Goats milk may have some immune-boosting and other benefits if you drink it, and some people believe that using it topically in the form of soap can provide the same benefits for skin conditions like eczema.

Theres little research that proves goats milk soap will work to treat eczema.

Heres what we do know about using goats milk soap, including whether its a safe home remedy for children and adults with eczema.

Goats milk soap hasnt been extensively tested for use as an eczema treatment. Here are the proven benefits of goats milk soap and how they might play into eczema treatment.

Goats milk contains lactic acid, a naturally occurring and gentle alpha-hydroxy acid (AHA). Lactic acid is even in some commercial-grade skin peels because of how effective it is at exfoliating and encouraging cell turnover. Cleansing your skin with goat milk soap may help dissolve dead skin cells, revealing healthy, younger skin cells underneath.

Lactic acid from goat milk also contains probiotics. Oral probiotics using lactic acid bacteria have been shown to help treat eczema in infants. Since these probiotics found in the lactic acid found in goat milk was an effective topical treatment in infants, it might be worth a try.

Lactic acid doesnt just add probiotics and exfoliate your skin. Lactic acid in goats milk, combined with the natural fats and oils in the milk, are a natural humectant. That means that goats milk soap may strengthen your skin barrier and seal moisture in. Skin thats well-hydrated may be more resistant to eczema flareups.

Goats milk soap is generally considered safe for everyone. That includes the soft, extra-sensitive skin of babies and children.

Youll also want to look at the other ingredients. If you have eczema, you may be all too familiar with cosmetics, soaps, and beauty products that claim to be all natural but trigger your symptoms and inflame your skin. Also be aware of what type of oils are contained in the soap. At least one study indicates that olive oil can make eczema symptoms worse for babies.

If youre considering bathing your little one with goats milk soap, run it by their pediatrician, especially if your baby is less than 1 year old. Also, keep in mind that goats milk soap is not a replacement for any skincare product a doctor has prescribed for your baby to treat eczema or psoriasis.

Some kids might have sensitivity to goats milk soap, so use a small amount the first time to test it out.

Goats milk soap works great for some people, but it isnt for everyone. A study published in 2017 noted that using goats milk soap for inflammatory skin conditions, such as eczema, may increase your likelihood of developing an allergic reaction to consuming goats milk and goats milk products. Research also suggests that absorbing certain ingredients through a compromised skin barrier can lead to food allergies later on.

If youre interested in using goats milk soap for eczema, you have a couple of options.

First, you need to find the right products. Goats milk soap can be made from a powder base, or from fresh goats milk. Anecdotally, people who swear by goats milk for eczema prefer fresh goats milk for maximum benefits.

If youd rather test your skins reaction to goats milk soap (or if youre trying it out on an infant), you can simply add a little bit of the soap to warm water in the tub to create a soothing bath. Just make sure to keep it away from infants eyes.

Goats milk soap is more readily available in the United States than its ever been.

You can buy goats milk soap at health food stores, natural beauty suppliers, organic supermarkets, and some pharmacies.

Shop for goat milk soap online.

The evidence we have to support using goats milk soap for eczema is mainly anecdotal. However, theres research to support other benefits of goats milk soap for your skin, some of which are linked to eczema management.

For most people, theres little harm in giving goats milk soap a try to treat eczema symptoms. If you have a goats milk allergy, you may want to steer clear. Consult your childs pediatrician if you have questions about trying goats milk soap to help treat eczema for your child.

Visit link:
Goat's Milk Soap for Eczema: Potential Benefits and Precautions - Healthline

The Sarna Eczema Relief Whipped Foam helps heal eczema flare-ups and provides fast, soothing relief. Featuring eN2fused technology, a patent-pending matrix-infused technology containing millions of compressed gas microbubbles that rapidly expand when dispensed, the maximum strength formula helps to prevent transepidermal water loss and improve skin's natural protective barrier.

"Consumer demand has increased for more elegant formulations that absorb quickly into the skin without leaving unwanted residue," said Steve Gallopo, Crown Therapeutics Vice President, Global OTC Sales & Marketing. "Sarna has had tremendous success and is uniquely positioned to improve the anti-itch category. This first-of-its-kind whipped foamtechnology drives the brand to the forefront of best-in-class, innovative skin science solutions."

"Sarna has always been my go-to recommendation for patients suffering from dry, itchy skin and eczema," said Dr. Hadley King, Board Certified Dermatologist, "I'm thrilled to be able to offer a new, easy to use, fast-absorbing option that delivers the relief that my patients need, especially for those who want a more lightweight formula for everyday use."

Sarna Eczema Relief Whipped Foam is now available via Amazon.

1IQVIA Health

About SarnaSarna is the #1 dermatologist-recommended topical anti-itch brand1. Offering a unique variety of formulations, each product in the collection is designed to provide fast-acting, intensive relief and comfort to compromised skin without a prescription. Sarna products provide powerful itch relief and are safe for everyday use, containing no parabens, dyes or added fragrance. For more information about Sarna, please visithttps://sarnalotion.com/

About CrownCrown, a privately held, fully integrated global skin care company is committed to developing and providing a diverse portfolio of aesthetic, beauty, and therapeutic skin care products that improve the quality of life for its customers. An innovative company focused on skin science for life, Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for seven years and has expanded its distribution to over 38 countries. For more information about Crown or its products, visitwww.crownlaboratories.com.

SOURCE Crown Laboratories, Inc.

Home

Read this article:
Sarna Launches First-of-Its-Kind Whipped Foam Eczema Relief Therapy - PRNewswire

A real-world assessment of dupilumab (Dupixent) show the biologic agent provides patients with atopic dermatitis consistent clinician- and patient-reported outcomes.

The interim PROSE registry findings, presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience this weekend, complement a litany of clinical trials observing the interleukin-4 and -13 (IL-4; IL-13) inhibitor for atopic dermatitis.

Investigators, led by Jerry Bagel, MD, of the Psoriasis Treatment Center of Central New Jersey, sought the early trends of real-world initiated dupilumab treatment from the PROSE registryan ongoing, multicenter, longitudinal observational database enrolling atopic dermatitis patients treated with dupilumab in the US and Canada for up to 5 years.

Randomized dupilumab clinical trials have demonstrated rapid and sustained long-term efficacy with an acceptable safety profile in patients with moderate-to-severe atopic dermatitis; however, real-world data are limited, Bagel and colleagues wrote.

Their assessment of the registry did not include imputation for missing values. Eligible patients were initiating dupilumab as standard of care for diagnosed atopic dermatitis, but were able to receive marketed drugs as prescribed by clinicians for either their disease or a comorbid condition.

At the data cutoff of July 2019, 315 patients were enrolled. Mean patient age was 42.5 years old, with 44.8% being male, and 59.4% being White. Mean baseline Eczema Area Severity Index (EASI) score was 16.9; duration of atopic dermatitis was 19.7 mean years.

By month 6 of real-world dupilumab care, mean EASI score decreased to 4.4. Mean body surface area affected by atopic dermatitis dropped from 26.8% at baseline to 7.2% at 6 months.

Patient-Oriented Eczema Measure (POEM) scores decreased from 18.5 at baseline to 6.9 at month 6. Investigators additionally observed decreases in Peak Pruritus Numerical Rating Scale (6.9 vs 2.5) and Mean Dermatology Life Quality Index (12.7 vs 4.4) in the observed time period.

This real-world study demonstrates improvement in atopic dermatitis in adults over the initial 6 months of dupilumab treatment, using investigator-assessed and patient-reported outcomes, Bagel noted in his presentation.

The study, Early Trends of Disease Improvement in Adult Patients With Atopic Dermatitis Treated With Dupilumab: Real-World Data From the PROSE Registry, was presented at AAD VMX.

Read the rest here:
Real-World Dupilumab Initiation Linked to Atopic Dermatitis Clearance at 6 Months - MD Magazine

The CHMP positive opinion is one of the final steps before the European Commission makes its decision on the Marketing Authorization Application for use of Adtralza, an investigational therapy in clinical development, throughout the European Union. This final decision is expected in the coming months and if authorized, Adtralza will be the first fully human, monoclonal antibody available to specifically target the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms. Adtralza specifically targets IL-13 with high affinity and is developed to improve the symptoms of atopic dermatitis, which is a complex and chronic inflammatory skin condition.1,2

Atopic dermatitis is characterized by its unpredictability, which can be challenging for patients who often experience physical discomfort and emotional effects that may continue for decades, said Jrg Mller, Executive Vice President, Global Research and Development, LEO Pharma. Todays CHMP opinion brings LEO Pharma one step closer to the potential of providing Adtralza as a new therapeutic option for EU patients living with moderate-to-severe atopic dermatitis.

The CHMP opinion is based primarily on data from three pivotal randomized, double-blind, placebo-controlled trials (ECZTRA 1, 2 and ECZTRA 3), which evaluated the safety and efficacy of Adtralza as monotherapy and with concomitant topical corticosteroids (TCS) in more than 1,900 adult patients with moderate-to-severe atopic dermatitis. Primary endpoints were the Investigator Global Assessment score of clear or almost clear skin (IGA 0/1) and at least a 75% improvement in the Eczema Area and Severity Index score (EASI-75).3,4

Secondary endpoints, including the extent and severity of skin lesions, pruritus (itch), sleep and health-related quality of life measures, were measured by changes in the following scores: EASI-90, SCORing Atopic Dermatitis (SCORAD), Pruritus Numeric Rating Scale (NRS), Eczema-Related Sleep NRS and Dermatology Life Quality Index (DLQI). The trials demonstrated that Adtralza met the primary and secondary efficacy endpoints and was generally well tolerated.3,4

Pending the final decision from the European Commission, the marketing authorization will be valid in all European Union Member States, Iceland, Norway, and Liechtenstein. Additional regulatory filings are underway [with the U.S. Food and Drug Administration (FDA)] and other health authorities worldwide.

About Adtralza (tralokinumab)

Adtralza (tralokinumab) is a fully human, monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby preventing interaction with the IL-13 receptor 1 and 2 subunits (IL-13R1 and IL-13R2).1,2

About the pivotal ECZTRA 1, 2, and ECZTRA 3 Trials

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab trials Nos. 1 and 2) were randomized, double-blind, placebo-controlled, multinational 52-week trials, which included 802 and 794 adult patients, respectively, to evaluate the safety and efficacy of Adtralza (300 mg) as monotherapy in adults with moderate-to-severe atopic dermatitis who were candidates for systemic therapy.3

ECZTRA 3 (ECZema TRAlokinumab trial No. 3) was a double-blind, randomized, placebo-controlled, multinational 32-week trial, which included 380 adult patients, to evaluate the safety and efficacy of Adtralza (300 mg) in combination with TCS in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.4

About atopic dermatitis

Atopic dermatitis (AD) is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.5 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.6 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.1

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. [In 2020, the company generated net sales of DKK 10,133 million]. For more information please visit http://www.LEO-Pharma.com

References

April 2021 MAT-42443

View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005296/en/

Continued here:
LEO Pharma Receives Positive CHMP Opinion of Adtralza (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis - BioSpace

The appearance of flushed skin around the nose varies from person to person. It can depend on the specific condition that causes it, how severe the irritation is, and a persons skin color.

Some people notice dry, itchy spots, raised or indented skin, or tiny blisters.

In people with dark skin, flushed skin around the nose may appear violet or purple. It may also be less noticeable, even when the rash is severe.

People with dark skin may also find that their doctors do not easily recognize the signs of various skin conditions. This may be due to dermatology textbooks that have focused on light-skinned patients.

For example, a 2020 study found that dermatologists might not recognize the skin manifestations of COVID-19 in Black patients. This can undermine their quality of care.

Learn about how rashes can look on dark skin here.

There are many different conditions or factors that could cause flushed skin around a persons nose.

Simply wiping the nose over and over can irritate the skin. This is especially the case during dry, cold months when the skin is more likely to be dry and irritated.

A person may notice that their skin looks red or purple, and the pain may worsen when they wipe their nose.

Some people develop mild allergic reactions to substances that touch their skin. Doctors call this contact dermatitis.

Irritant contact dermatitis irritates the skin but does not cause an allergic reaction. It may cause flushed skin and a raised rash, but the rash should not spread or cause a fever.

Causes of irritant contact dermatitis on the nose may include:

Symptoms of allergic contact dermatitis, such as a rash, may appear 2 days after a person has come into contact with an allergen.

Some causes may include fragrances and the preservative thimerosal, which features in some antibiotic creams.

Less commonly, a person may develop a life-threatening allergic reaction called anaphylaxis. This usually happens within a few minutes of exposure to an allergen.

Anaphylaxis may begin as a rapidly spreading rash. If a person sees a rash on their nose, they should check their body for bumps or other rashes.

Anaphylaxis is a medical emergency. If a person sees a spreading rash or has trouble breathing, they should call 911.

Rosacea is a skin condition that causes flushed skin and inflammation. While rosacea can affect any part of the body, it often begins around the nose.

A person might notice flushed skin, damaged blood vessels, tiny bumps, or changes in the shape of the nose. Rosacea is not dangerous, but it can affect a persons appearance.

In some people, rosacea may also be a sign of an underlying illness, such as an autoimmune disease.

Rosacea is more prevalent in people between the ages of 30 and 50 and in those with light skin. It is more likely to affect females than males.

Discover the best skin care products for rosacea here.

Eczema is a chronic inflammatory skin condition that causes dry, irritated patches of skin.

Sometimes the irritation is so severe that the patches crack open and bleed. Allergens and irritation can trigger an eczema flare, but dry skin is also a common culprit.

Redness around the nose may be eczema if it feels dry and itchy, looks white, red, or flaky, and worsens when the skin is dry.

Learn about what eczema can look like on black skin here.

A person can develop a sunburn just around their nose if they:

If the redness is flat and turns flesh-colored when a person presses on it, it may be a sunburn.

Sunburn may also feel dry and very sore. Severe sunburns sometimes blister.

Sunburn is a risk factor for skin cancer.

African American people have a lower melanoma survival rate than Caucasians. This may be due to delays in care.

Learn about how sunburn affects dark skin here.

An infection at the entrance of the nose called nasal vestibulitis can cause flushed skin and tiny, blister-like bumps around the nose and just inside of it.

A person may feel pain, swelling, and intense sensitivity. Some people develop a fever, though a person does not have to have a fever to have vestibulitis.

Nasal vestibulitis happens when bacteria enter the skin of the nose, often following an injury or infection. It can happen after a person trims their nose hairs.

Nasal vestibulitis is easy to treat, but it can spread to other areas of the body, so it is important to see a doctor.

Veins, which carry blood back to the heart, have valves in them to prevent blood from flowing the wrong way.

However, when these valves become damaged, the veins may look damaged and twisted. These are known as varicose veins.

Varicose veins often occur in the legs and feet. They especially happen in pregnant people and those who are overweight or obese. However, a person can develop varicose veins anywhere, including the nose.

The nose may look red, but when a person looks more closely, they might see tiny damaged blood vessels.

Learn 10 home remedies for varicose veins here.

Lupus is an autoimmune condition that causes the body to attack healthy tissue, leading to a wide range of symptoms and chronic illnesses.

Some people with lupus develop a malar rash, also known as a butterfly rash because it resembles a butterfly. This rash can cover the nose and cheeks.

In some cases, the butterfly rash may be the first symptom of lupus.

Learn about more symptoms of lupus here.

Infections of the skin can cause red, painful skin that may feel hot to the touch.

Cellulitis, one such infection, can begin with an injury even a small one. It might be as simple as dry, cracked skin. Bacteria gets into the deep layer of skin, called the dermis, and begins spreading. A person might notice flushed streaks, heat, pain, or swelling.

Bacterial skin infections can spread to other areas of the body, potentially even endangering a persons life. Therefore, it is important to seek prompt care.

See pictures of skin infections here.

Continued here:
Redness around nose: Causes, treatment, home remedies, and more - Medical News Today

Published April 26, 2021 by Tamsin Hackett

Ebury Press will publish singerEmma Bunton's first book, Mama You Got This, on 10th June 2021.

Ebury Press will publish singerEmma Bunton's first book, Mama You Got This, on 10th June 2021.

Laura Higginson, editorial director, bought world all language rights from Severine Berman at The Mutha Ship.

Bunton is a mum of two and like most new parents, she juggled being a working mum, partner, friend, and trying to find time for herself, says the publisher. Although she had supportive friends and family, she found the endless rules and strict routines of most baby books overwhelming.

Mama You Got This is the book Bunton wishes she had readwhen she was a new mum.She will share the highs and lows she experienced,from post-birth recovery and no sleep to playtime and first smiles and share what she has learnt and some funny stories along the way. The author will also discuss her baby-care range Kit & Kin which she launched in 2017 after her child Tate suffered with chronic eczema.

The information in the book will be backed by experts including Yales paediatric sleep consultant Dr Craig Canapari, NCT breastfeeding expert Fran Bailey, mindfulness coach Heidi Fultonand midwife Marley Hall who will offer tips aboutsleeping, breastfeeding, weaning, crying, feeding, playing and self-care.

Higginson said: "Emma is known for being Baby Spice, full of girl power. I loved hearing about the very personal other side of her life and all those secret stories from being a mum whilst being one of the most famous pop stars on the planet. Her motivation for launching Kit and Kinto make a positive difference to baby-care and the planet is really inspiring and Emmas passion to write an equally positive, accessible modern guide is really exciting its a modern mum bible rich with relatable stories that will leave readers laughing, crying and feeling like whatever they are dealing with, they are not alone and there is help."

Bunton commented: "For my first ever book, writing about the most important part my life was easy. Opening up and sharing my stories feels totally natural with all you mums who are going through the same experiences but all in our own unique way. Becoming a mummy can be so daunting but we are in this together and we can support each other, dont you worry, mama,youve got this!"

The rest is here:
Ebury to spice up the summer with Bunton's 'modern mum bible' - The Bookseller

When the pandemic really started to take a stranglehold on Jamaica, I made a decision to try and grow a beard.

I even wrote about it here in this column. Now that decision came after months of not going to the barbershop because mi nuh waan ketch COVID jus because me a try look decent. I realised that the old facial hair had grown so much, it didnt feel right to get rid of it.

Then I started perusing social media and the Internet to see what hairstyles would complement the new look. Found something I thought would work. First time I went to the barber circa August (remember COVID reach yah March) I felt boasy. Even posted on social media and everything.

But its been all downhill since then. You see, I have a little issue called eczema but when all the creams and medicinal shampoos are working its all good. But once that hair starts to get to a certain height and thickness, God help you! Then before you know, because of work and other stresses, the hair washing and maintenance schedule gets thrown out of whack. So instead of washing the hair twice a week, you end up doing it once a week. And whereas in the early weeks of the growth you knew the hair-care products were getting to the scalp, it turns out to be less so as the hair gets more clumped.

So the semi-matted look became just matted and messy real quick. And like I said, yours truly has an eczema issue. As anyone who knows about that stuff will tell you, stress and other factors like failure to keep the scalp moisturised, will have rather negative effects. I found that out the hard way recently. Had to go to the barber and bruh, it was not pretty. Good thing my barber is cool (Dre big up yuhself) because my head never look good at all! I felt like Naaman the leper in the Bible.

Since then Ive been using a regimented schedule of washing the rapidly re-growing hair (I decided to shave it bald) and using good ol aloe vera to keep things presentable. Ill update you on how its going another time.

The reason for the column this week is to tell all of us who like to criticise women for doing what we consider too much for beauty, should really shut up. Look, it takes work to keep yourself looking decent. Note Im not talking about looking glamorous. Im just talking about looking normal. Even if youre only using natural products, you have to be disciplined. So if we are talking about even more exotic looks, it must take even more effort. We all have the right to feel good about ourselves. So if some people, especially women, put tremendous labour into their appearance, even if we dont think it looks good, who are we to judge?

Everyone should be free to look their best, regardless of what they consider their best to be.

Link me at daviot.kelly@gleanerjm.com

See more here:
Can't argue with women on this beauty thing - Jamaica Gleaner